New drug combo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that has spread to other parts of the body.
- You have already tried one type of treatment for your advanced cancer, but it stopped working or you had side effects.
- You are at least 18 years old.
- You are in fairly good health overall (able to do daily activities without much help).
- Your liver, kidneys, and blood cell counts are working well enough.
- You have not had gemcitabine or nab-paclitaxel before for advanced cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a combination of chemotherapy with two newer drugs (SHR-1701 and apatinib) as the first treatment for advanced pancreatic cancer. The goal is to see if this combination is safe and effective in slowing cancer growth.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.